000276077 001__ 276077
000276077 005__ 20240229154955.0
000276077 0247_ $$2doi$$a10.1055/a-2070-7572
000276077 0247_ $$2pmid$$apmid:37172610
000276077 0247_ $$2ISSN$$a0300-8630
000276077 0247_ $$2ISSN$$a1439-3824
000276077 037__ $$aDKFZ-2023-00983
000276077 041__ $$aGerman
000276077 082__ $$a610
000276077 1001_ $$00000-0002-3216-8452$$aObrecht, Denise$$b0
000276077 245__ $$aPediatric Intracranial Ependymoma - Recommendations for First-Line Treatment from the German HIT-MED study group.[Kinder und Jugendliche mit intrakraniellem Ependymom – Empfehlungen der HIT-MED-Studiengruppe der GPOH zur Erstlinientherapie].
000276077 260__ $$aStuttgart$$bThieme$$c2023
000276077 3367_ $$2DRIVER$$aarticle
000276077 3367_ $$2DataCite$$aOutput Types/Journal article
000276077 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1685440437_28112
000276077 3367_ $$2BibTeX$$aARTICLE
000276077 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000276077 3367_ $$00$$2EndNote$$aJournal Article
000276077 520__ $$aBiological subtypes of ependymoma (EPN) have been introduced by the recent WHO classification and appear to have great impact on the clinical course, but have not yet found their way into clinical risk stratification. Further, the overall unfavorable prognosis underlines the fact that current therapeutic strategies need further evaluation for improvement. To date, there is no international consensus regarding first-line treatment for children with intracranial EPN. Extent of resection is known to be the most important clinical risk factor, leading to the consensus that consequent evaluation for re-surgery of postoperative residual tumor needs to have highest priority. Furthermore, efficacy of local irradiation is unquestioned and recommended for patients aged>1 year. In contrast, efficacy of chemotherapy is still under discussion. The European trial SIOP Ependymoma II aims at evaluating efficacy of different chemotherapy elements, leading to the recommendation to include German patients. The BIOMECA study, as biological accompanying study, aims at identifying new prognostic parameters. These results might help to develop targeted therapies for unfavorable biological subtypes. For patient who are not qualified for inclusion into the interventional strata, the HIT-MED Guidance 5.2 provides specific recommendations. This article is meant as an overview of national guidelines regarding diagnostics and treatment as well as of treatment according to the SIOP Ependymoma II trial protocol.
000276077 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000276077 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000276077 650_2 $$2MeSH$$aChild
000276077 650_2 $$2MeSH$$aHumans
000276077 650_2 $$2MeSH$$aBrain Neoplasms: drug therapy
000276077 650_2 $$2MeSH$$aBrain Neoplasms: pathology
000276077 650_2 $$2MeSH$$aPrognosis
000276077 650_2 $$2MeSH$$aCombined Modality Therapy
000276077 650_2 $$2MeSH$$aRisk Factors
000276077 650_2 $$2MeSH$$aEpendymoma: diagnosis
000276077 650_2 $$2MeSH$$aEpendymoma: therapy
000276077 650_2 $$2MeSH$$aEpendymoma: pathology
000276077 7001_ $$aMynarek, Martin$$b1
000276077 7001_ $$aStickan-Verfürth, Martina$$b2
000276077 7001_ $$aBison, Brigitte$$b3
000276077 7001_ $$aSchüller, Ulrich$$b4
000276077 7001_ $$0P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aPajtler, Kristian$$b5$$udkfz
000276077 7001_ $$aHagel, Christian$$b6
000276077 7001_ $$aThomale, Ulrich-Wilhelm$$b7
000276077 7001_ $$00000-0001-5714-007X$$aFleischhack, Gudrun$$b8
000276077 7001_ $$aTimmermann, Beate$$b9
000276077 7001_ $$aRutkowski, Stefan$$b10
000276077 773__ $$0PERI:(DE-600)2039110-9$$a10.1055/a-2070-7572$$gVol. 235, no. 3, p. 167 - 177$$n3$$p167 - 177$$tKlinische Pädiatrie$$v235$$x0300-8630$$y2023
000276077 909CO $$ooai:inrepo02.dkfz.de:276077$$pVDB
000276077 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000276077 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000276077 9141_ $$y2023
000276077 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-22
000276077 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-22
000276077 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-08-28$$wger
000276077 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bKLIN PADIATR : 2022$$d2023-08-28
000276077 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-28
000276077 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-28
000276077 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-28
000276077 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-28
000276077 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-28
000276077 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-28
000276077 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000276077 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000276077 980__ $$ajournal
000276077 980__ $$aVDB
000276077 980__ $$aI:(DE-He78)B062-20160331
000276077 980__ $$aI:(DE-He78)HD01-20160331
000276077 980__ $$aUNRESTRICTED